Breaking News

Crucell, Talecris Biotherapeutics Sign License Agreement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Crucell has signed an exclusive, commercial license agreement with NC-based Talecris Biotherapeutics for an undisclosed protein to be produced using the PER.C6 cell line. Crucell will receive an upfront payment of $2.5 million and will be eligible for milestone payments of approximately $30 million across multiple indications. Further details were not disclosed....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters